Platformbiorreactores
The initiative of the purchase of innovation of aBiorreactores platform refers to pre-commercial procurement of services of r & D for the development of a platform of biorreactores single use for the production of based biofármacos autólogas cells.
The CPP-Biorreactores is included and aligned with theLOSS to the health of Vanguardand, in particular, within the action called "incorporation of techniques and technologies in the national health system"
Need raised by a Public Administration
The Cellular therapy treatments based autólogas cells are one type of Personalized Medicine, as they have to obtain the cells of the patient himself, modify and re-infundirlas in the patient to implement them. There is now a huge demand in the national health system (SNS) of this type of cell therapies autólogas realizandose cells, handling, exclusively or mainstream, in the nhs hospital themselves.
The benefits to citizens and for the sustainability of the SNS medicine precision Custom based autólogas cells are visible, so it is critical to have new techniques and technologies that provide production capacity more versatile, standardized and automated and advanced control systems for compliance with the Perfect Manufacture. This type of platforms of the capacities of Transfer of Good practices in Use can contribute to the deployment of personalized medicine based autologous treatment in the national health system.
Public administration user
The technological challenge raised
The activity is primarily aimed at developing the technology needed to create a prototype of platform that includes integrated three subsystems: (i) New Bioreactor that use of equipment of a single use, (ii) New Intelligent Platform management Biorreactores parallel and (iii) New Platform of Intelligent Transfer of Good practices in Use. The platform for Biorreactores composed of three subsystems may validated as a single prototype in conditions in real pre-operacionales health research centre.
The techniques based on artificial intelligence can discuss the production processes and identify at a faster pace of Optimal cultivation patterns specific cell type; expediting the decision-making process in the detection; and accelerate the transfer of good practice for different types of cells autólogas.
TenderCPP 06/2023 AB (OF/OCIE)
The milestones of the platform for biorreactores initiative are as follows:
- Conclusion- Has been published in the beijing platform for Recruitment of the public Sector (PLACSP) theconclusion of contractscontracting companies of the CPP Biorreactores - [13 march 2024]
- Award- Has been published in the beijing platform for Recruitment of the public Sector (PLACSP) theawardthe CPP of Biorreactores - [29 february 2024]
- Tender-publication of the Pre-Commercial Public Procurement of services of r & D in the area of biorreactores platforms single-use production based biofármacos autólogas cells- [5 november 2023]
- Report of findings of the jpc-publication report of findings of the preparatory consultation of the market (CPM)- [19 may 2023]
- Day of submission of the jpc-Agenda of the technical workshop for the submission of the technological challenge of the jpc- [22 february 2023]
- Convening of the reopening of the preparatory consultation of the market (CPM)-publication of the Resolution of Reopening of the jpc- [31 january 2023]
- Day of submission of the jpc-Agenda and presentations of the day of submission of the jpc- [2 november 2002]
- Convening of the preparatory consultation of the market (CPM)-Resolution of the publication of the jpc in biorreactores platforms single-use production based biofármacos autólogas cells- [7 february 2002]
This initiative isfundedwith funding from ofMechanism for the recovery and resilience.
